The remainder of this review summarizes evidence of the clinical relevance and therapeutic potential of CD47 in NSCLC, strategies for achieving CD47 blockade that are currently being developed and evaluated in clinical trials, and key challenges associated with translating CD47-targeted therapy into oncology clinics. Here, CD47 is linked to non-small cell lung carcinoma.